If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Before the British prime minister left Rhodesia on 30 October 1965, he proposed a Royal Commission to gauge public opinion in the colony regarding independence under the 1961 constitution, possibly chaired by the Rhodesian Chief Justice Sir Hugh Beadle, which would report its findings to both the British and Rhodesian Cabinets. Wilson confirmed in the House of Commons two days later that he intended to introduce direct British control over the Rhodesian parliamentary structure to ensure that progress was made towards majority rule. Stalemate drew closer as the Rhodesian Cabinet resolved that since Wilson had ruled out maintenance of the status quo, its only remaining options were to trust in the Royal Commission or declare independence. When the terms for the commission's visit were presented to Smith, he found that contrary to what had been discussed during the British prime minister's visit, the Royal Commission would operate on the basis that the 1961 constitution was unacceptable to the British government, and that Britain would not commit itself to accepting the final report. Smith said these conditions amounted to a "vote of no confidence in [the commission] before they commenced", and therefore rejected them. "The impression you left with us of a determined effort to resolve our constitutional problem has been utterly dissipated", he wrote to Wilson on 5 November.
In lichenology, simple chemical spot tests are used to detect certain compounds in situ, and X. parietina yields clear results due to its anthraquinone pigments. A standard test is the K test (using potassium hydroxide solution). On X. parietina, applying KOH to the cortex produces a deep purple reaction (K+ purple). This is a classic indication of anthraquinones like parietin – the KOH causes parietin to form a purple salt (a distinctive color change). Other spot test results for this lichen are negative: C−, KC−, and P−. In addition to its anthraquinone pigments, Xanthoria parietina contains small amounts of calcium oxalate, a secondary metabolite that occurs in many lichens, particularly those growing on calcareous substrates. However, unlike strictly calcicolous species such as Caloplaca heppiana and Lecanora calcarea, which accumulate large quantities of calcium oxalate, X. parietina was found to contain only minor traces of this compound. This suggests that while X. parietina can tolerate limestone habitats, it does not rely on extensive oxalate production for calcium regulation or substrate modification to the same extent as obligate calcicoles.
In a speech to Mansion House, Andrew Bailey, the governor of the Bank of England, says the UK must "rebuild relations" with the EU "while respecting the decision of the British people" who voted for Brexit. Neil Gray, Scotland's Health and Social Care Secretary, apologises to the Scottish Parliament for not attending a "wider range" of football matches after he used a chauffeur driven vehicle to attend four games at Aberdeen F.C., something he says gave the impression he was acting "more as a fan and less as a minister". 15 November – A report by the National Audit Office reveals that the Home Office "cut corners" and made "poor decisions", while under pressure to stop housing migrants in hotels, when it purchased the former HM Prison Northeye for £15m in 2023; the site was derelict and contaminated with asbestos. 10 Downing Street apologises after meat and alcohol were served at a Diwali celebration held there in October. Stephen McCabe resigns as leader of Inverclyde Council after appearing in court charged with assault and threatening behaviour. Northern Ireland Communities Minister Gordon Lyons attends a football match between Northern Ireland and Belarus despite UK government guidance that the game should not go ahead because of sanctions against Belarus over its stance over the Ukraine War.
=== Flammability === Metallic plutonium is a fire hazard, especially if finely divided. In a moist environment, plutonium forms hydrides on its surface, which are pyrophoric and may ignite in air at room temperature. Plutonium expands up to 70% in volume as it oxidizes and thus may break its container. The radioactivity of the burning material is another hazard. Magnesium oxide sand is probably the most effective material for extinguishing a plutonium fire. It cools the burning material, acting as a heat sink, and also blocks off oxygen. Special precautions are necessary to store or handle plutonium in any form; generally a dry inert gas atmosphere is required.
Sources: en.wikipedia.org
Febris (fever in Latin) is the goddess of fever in Roman mythology. People with fevers would visit her temples. Tertiana and Quartana are the goddesses of tertian and quartan fevers of malaria in Roman mythology. Jvarasura (fever-demon in Hindi) is the personification of fever and disease in Hindu and Buddhist mythology.
Static-active stretching includes holding an extended position with just the strength of the muscles such as holding the leg in front, side or behind. Static-active flexibility requires a great deal of strength, making it the hardest to develop.
=== Pharmacodynamics === Sarcosine acts as a competitive inhibitor of GlyT1, a glycine transporter that is predominantly expressed on glial cells and is responsible for the reuptake of glycine from the synaptic cleft in the central nervous system. By blocking GlyT1, sarcosine elevates the extracellular concentration of glycine in the vicinity of NMDA receptors, thereby augmenting NMDA receptor-mediated neurotransmission. In addition to its indirect enhancement of NMDA receptor function via GlyT1 blockade, sarcosine directly acts as a co-agonist at the glycine binding site (also termed the GluN1 site) of the NMDA receptor. It increases NMDA-mediated currents in a dose-dependent manner. Sarcosine differs from glycine as a co-agonist in that it produces markedly less NMDA receptor desensitization at subsaturating concentrations. At equivalent receptor occupancy (EC20 to EC50), sarcosine significantly slowed the rate of glycine-dependent desensitisation compared with glycine itself, whereas the rate of glycine-independent desensitisation was similar for both ligands. At concentrations higher than those required for GlyT1 inhibition or NMDA receptor co-agonism, sarcosine additionally activates strychnine-sensitive glycine receptors (GlyRs). It evokes a chloride current that is dose-dependent, inhibited by strychnine, and shows a lack of additivity with glycine. Sarcosine is less potent and efficacious than glycine at GlyRs, potentially due to steric constraints imposed by the N-methyl group within the glycine binding site on the receptor.
=== Portland cement blend === Portland cement blends are often available as inter-ground mixtures from cement producers, but similar formulations are often also mixed from the ground components at the concrete mixing plant. Portland blast-furnace slag cement, or blast furnace cement (ASTM C595 and EN 197-1 nomenclature respectively), contains up to 95% ground granulated blast furnace slag, with the rest Portland clinker and a little gypsum. All compositions produce high ultimate strength, but as slag content is increased, early strength is reduced, while sulfate resistance increases and heat evolution diminishes. Used as an economic alternative to Portland sulfate-resisting and low-heat cements. Portland-fly ash cement contains up to 40% fly ash under ASTM standards (ASTM C595), or 35% under EN standards (EN 197–1). The fly ash is pozzolanic, so that ultimate strength is maintained. Because fly ash addition allows a lower concrete water content, early strength can also be maintained. Where good quality cheap fly ash is available, this can be an economic alternative to ordinary Portland cement. Portland pozzolan cement includes fly ash cement, since fly ash is a pozzolan, but also includes cements made from other natural or artificial pozzolans. In countries where volcanic ashes are available (e.g., Italy, Chile, Mexico, the Philippines), these cements are often the most common form in use. The maximum replacement ratios are generally defined as for Portland-fly ash cement. Portland silica fume cement.
Idiopathic pulmonary fibrosis (IPF): the most common subgroup, representing more than 30% of ILD Desquamative interstitial pneumonia (DIP) Acute interstitial pneumonia (AIP): also known as Hamman-Rich syndrome Nonspecific interstitial pneumonia (NSIP) Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) Cryptogenic organizing pneumonia (COP): also known by the older name bronchiolitis obliterans organizing pneumonia (BOOP) Lymphoid interstitial pneumonia (LIP)
Sources: en.wikipedia.org
== Mode of action == It is believed that ω-grammotoxin SIA inhibits channel function by binding with high affinity to closed, resting states of the channel and that bound toxin makes it more difficult for channels to be opened by depolarization, so much larger depolarizations are required for channel activation.
== Treatment == In May 2023, the US Food and Drug Administration (FDA) approved Vyjuvek for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
However, on April 9, Dana White, the president of UFC announced that this event was postponed to a future date Instead Casey is scheduled to face Mara Romero Borella on May 16, 2020 at UFC on ESPN: Overeem vs. Harris. She won the bout in the first round via submission through an armbar. This win earned her the Performance of the Night award. Casey faced Gillian Robertson on June 20, 2020 at UFC Fight Night: Blaydes vs. Volkov. She lost the fight via a rear-naked choke submission in round three. Casey was expected to face Priscila Cachoeira on October 31, 2020 at UFC Fight Night 181. However the bout was called off the day of the weigh-ins as Cachoeira had issues cutting weight. Casey faced JJ Aldrich on March 13, 2021 at UFC Fight Night 187. She lost the fight via split decision. Casey was expected to face Liana Jojua on August 21, 2021 at UFC on ESPN 29. However, Jojua was forced out of the fight due to visa issues. The matchup was rescheduled at UFC Fight Night 197 on November 13, 2021. At the weigh-ins, Jojua weighed in at 128.5 pounds, two and a half pounds over the flyweight non-title fight limit. The bout proceeded at a catchweight with Jojua fined 30% of her purse, which went to her opponent Casey. Casey won the bout via unanimous decision. Casey was scheduled to face Antonina Shevchenko on April 30, 2022 at UFC on ESPN 35. However, the bout was postponed to July 9, 2022 at UFC on ESPN 39 due Shevchenko injured her knee in training. Casey lost the fight via split decision. Casey was scheduled to face Jasmine Jasudavicius on February 25, 2023, at UFC Fight Night 220.
Recent single-molecule tracking experiments in live E. coli showed an ongoing but slower protein synthesis upon treatment with different aminoglycoside drugs. (Spectinomycin, a related but distinct chemical structure class often discussed with aminoglycosides, does not induce mRNA misreading and is generally not bactericidal.)
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.